Assessment of lupus anticoagulant in anti-cardiolipin and/ or anti-β2GPI sero-positive patient: Clinicopathological perspective from a tertiary care lab in Pakistan
DOI:
https://doi.org/10.55629/pakjpathol.v36i3.915Abstract
Objective: To assess the frequency of Lupus anticoagulant in patients seropositive for anti-cardiolipin and/or anti Beta-2 glycoprotein (anti-β2GPI) antibodies, and to explore potential clinicopathological correlations.
Material and Methods: This Observational Cross-sectional study was conducted at the Department of Immunology, AFIP Rawalpindi from January 2022 to October 2024. A total of 108 samples seropositive for anti-cardiolipin and/or anti-β2GPI antibodies were selected and further investigated for Lupus anticoagulant. Patients were stratified into single, double and triple positivity based upon their aPL profile. Chi-square test were used to find significant association among these aPL profiles. Mann-Whitney U test was used to compare age in LA-positive and negative groups. p-value <0.05 was considered statistically significant.
Results: Out of 108 samples analyzed, the LA positivity was observed in 13 (12%) patients and was significantly associated with younger age (median: 29 vs. 37 years, p = 0.041), but not with gender. Among cases positive for aCL IgG and aβ2GPI IgG (including dual positive cases),12 (11.1%) and 2 (1.9%) were LA-positive, respectively. No association was observed between individual antibody positivity and LA (p = 0.457 for aCL IgG; p = 0.221 for aβ2GPI IgG). Dual positivity for aCL IgG and aβ2GPI IgG did not significantly increase LA positivity, and triple positivity (aCL IgG + aβ2GPI IgG + LA) was rare (0.9%).
Conclusion: To conclude, Lupus anticoagulant was detected in a subset of anti-cardiolipin and/or anti-β2GPI seropositive patients, with a significant association observed with younger age.
Keywords: Antiphospholipid antibodies, Antiphospholipid Syndrome, Autoimmune disorder, Lupus anticoagulant.
References
Bustamante JG, Goyal A, Rout P, Singhal M. Antiphospholipid syndrome. StatPearls [Internet]: StatPearls Publishing; 2024. Available from https://www.ncbi.nlm.nih.gov/sites/books/NBK430980/
Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, et al. The 2023 ACR/ EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol. 2023; 75(10): 1687-702. DOI: https://doi.org/10.1002/art.42624
Grygiel-Górniak B, Mazurkiewicz Ł. Positive antiphospholipid antibodies: Observation or treatment? J Thromb Thrombolysis. 2023; 56(2): 301-14. DOI: https://doi.org/10.1007/s11239-023-02834-6
Dabit JY, Valenzuela-Almada MO, Vallejo-Ramos S, Duarte-García A. Epidemiology of antiphospholipid syndrome in the general population. Curr Rheumatol Rep. 2021; 23(12): 85. DOI: https://doi.org/10.1007/s11926-021-010 38-2
Pericleous C, D’Souza A, McDonnell T, Ripoll VM, Leach O, Isenberg D, et al. Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events? Rheumatol. 2020; 59(1): 146-52. DOI: https://doi.org/10.1093/rheumatology/kez239
Mushtaq MZ, Ali SA, Sattar Z, Mahmood SBZ, Amber T, Riaz M. A retrospective review of antiphospholipid syndrome from a South Asian country. Arch Rheumatol. 2021; 37(1): 31. DOI: https://doi.org/10.46497/archrheumatol.2022.8979
Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood, J Am Soc Hematol. 2003; 101(5): 1827-32. DOI: https://doi.org/10.1182/blood-2002-02-0441
Kempers EK, Dalm VA, van Rijn MJE, Mulders AG, Leebeek FW, de Maat MP, et al. Indication and outcome of lupus anticoagulant and antiphospholipid antibodies testing in routine clinical practice. Rheumatol Adv Pract. 2021; 5(3): rkab093. DOI: https://doi.org/10.1093/rap/rkab093
Spegiorin LC, Galão EA, Bagarelli LB, Oliani AH, de Godoy JM. Prevalence of anticardiolipin antibodies in pregnancies with history of repeated miscarriages. Open Rheumatol J. 2010; 4: 28-30. DOI: https://doi.org/10.2174/1874312901004010028
Knight JS, Branch DW, Ortel TL. Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ. 2023; 380. DOI: https://doi.org/10.1136/bmj-2021-069717
Emmi G, Silvestri E, Squatrito D, Ciucciarelli L, Cameli AM, Denas G, et al. An approach to differential diagnosis of antiphospholipid antibody syndrome and related conditions. Sci World J. 2014; 2014(1): 341342. DOI: https://doi.org/10.1155/2014/341342
Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. New Engl J Med. 2018; 378(21): 2010-21. DOI: https://doi.org/10.1056/nejmra1705454
Ahsan O, Ahmed I, Shabbir M, Ahmed I. Frequency of antiphospholipid syndrome in deep vein thrombosis. Pak Armed Forces Med J. 2008; 58(4): 397-400. Available from: https://www.pafmj.org/PAFMJ/arti cle/view/1920/1663
Neville C, Rauch J, Kassis J, Solymoss S, Joseph L, Belisle P, et al. The persistence of anticardiolipin antibodies is associated with an increased risk of the presence of lupus anticoagulant and anti-β 2-glycoprotein I antibodies. Rheumatology. 2006; 45(9): 1116-20. DOI: https://doi.org/10.1093/rheumatology/kel050
Sciascia S, Willis R, Pengo V, Krilis S, Andrade D, Tektonidou MG, et al. The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. Thrombosis research. 2019;175:32-6. DOI: https://doi.org/10.1016/j.thro mres.2019.01.010
Ayyub M, Khan MN, Anwar M, Waqar A, Ali W, Hussain T, et al. Clinicopathological features of lupus anticoagulant; experience at AFIP during last seven years. Med Sci Monit. 2005; 11(11): CR536-539 :Available from: https://medscimonit.com/abstract/index/idArt/430368
Colling ME, Ay C, Kraemmer D, Koder S, Quehenberger P, Pabinger I, et al. Lupus anticoagulant test persistence over time and its associations with future thrombotic events. Blood advances. 2022; 6(10): 2957-66. DOI: https://doi.org/10.1182/bloodadvances.2021006011
Tincani A, Andreoli L, Casu C, Cattaneo R, Meroni P. Antiphospholipid antibody profile: Implications for the evaluation and management of patients. Lupus. 2010; 19(4): 432-5. DOI: https://doi.org/10.1177/0961203310361491
Bertin D, Camoin‐Jau L, Veit V, Resseguier N, Lambert M, Delmas PB, et al. Single or triple positivity for antiphospholipid antibodies in “carriers” or symptomatic patients: Untangling the knot. J Thromb Haemostasis. 2021; 19(12): 3018-30. DOI: https://doi.org/10.1111/jth.15518
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Mustajab Alam, Muhammad Sulaiman, Muhammad Hussain, Muhammad Aftab Hassan, Muhammad Zain ul abdeen javed, Muhammad Sohaib Hassan

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
